Tempus AI, Inc. (NASDAQ:TEM) Stock Now Rated “Hold” by Sell-Side Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have received a consensus rating of “Hold” from the twenty-two ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $79.37.

A number of equities analysts have issued reports on the company. Raymond James Financial set a $80.00 price target on Tempus AI in a research report on Wednesday, September 2nd. Jefferies Financial Group upgraded Tempus AI from an “underperform” rating to a “hold” rating and boosted their price objective for the company from $35.00 to $70.00 in a research report on Tuesday, November 3rd. Roth Capital initiated coverage on Tempus AI in a research note on Tuesday, September 8th. They set a “neutral” rating and a $67.00 target price for the company. Guggenheim upped their target price on Tempus AI from $65.00 to $92.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Weiss Ratings upgraded Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, October 13th.

Tempus AI Stock Performance

TEM opened at $75.89 on Friday. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 2.48. The firm has a fifty day moving average price of $72.70 and a 200 day moving average price of $57.51. Tempus AI has a 1 year low of $40.77 and a 1 year high of $89.09. The stock has a market cap of $13.84 billion, a P/E ratio of -71.59 and a beta of 3.61.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative net margin of 12.54% and a negative return on equity of 47.00%. The company had revenue of $411.54 million for the quarter, compared to analyst estimates of $409.39 million. During the same quarter last year, the business earned ($0.46) earnings per share. The firm’s revenue was up 23.1% on a year-over-year basis. Equities research analysts anticipate that Tempus AI will post -1.20 earnings per share for the current year.

Insider Buying and Selling

In other Tempus AI news, CAO Ryan Bartolucci sold 7,062 shares of the company’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $529,650.00. Following the completion of the transaction, the chief accounting officer directly owned 60,804 shares in the company, valued at approximately $4,560,300. This represents a 10.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $70.36, for a total transaction of $17,590,000.00. Following the transaction, the chief executive officer directly owned 50,000 shares in the company, valued at approximately $3,518,000. The trade was a 83.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,237,227 shares of company stock worth $85,388,983 in the last 90 days. 24.26% of the stock is owned by insiders.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. raised its holdings in Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Pictet Asset Management Holding SA lifted its stake in Tempus AI by 2,965.7% in the 3rd quarter. Pictet Asset Management Holding SA now owns 502,897 shares of the company’s stock worth $41,233,000 after purchasing an additional 486,493 shares in the last quarter. First Trust Advisors LP lifted its stake in Tempus AI by 90.3% in the 3rd quarter. First Trust Advisors LP now owns 456,624 shares of the company’s stock worth $37,397,000 after purchasing an additional 216,692 shares in the last quarter. Finally, Eagle Health Investments LP purchased a new position in Tempus AI in the 1st quarter worth approximately $11,588,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.